Core Insights - The primary results from the MAPLE-HCM trial indicate that aficamten demonstrates superiority over the standard-of-care beta-blocker metoprolol in improving exercise capacity in patients with obstructive hypertrophic cardiomyopathy (oHCM) [1][2][3] Company Overview - Cytokinetics is a biopharmaceutical company focused on developing treatments for cardiac muscle dysfunction, with aficamten being a key investigational drug currently under regulatory review in the U.S. and Europe [17][14] - Aficamten is a selective cardiac myosin inhibitor designed to reduce myocardial hypercontractility associated with hypertrophic cardiomyopathy (HCM) [11][12] Clinical Trial Details - The MAPLE-HCM trial is a Phase 3 randomized, double-blind study that enrolled 175 patients, comparing aficamten to metoprolol [2][4] - The primary endpoint was the mean change in peak oxygen uptake (pVO2) after 24 weeks, showing a significant improvement with aficamten (+1.1 mL/kg/min) compared to a decline with metoprolol (-1.2 mL/kg/min) [4][6] Efficacy Results - Aficamten showed a statistically significant least-squares mean difference of 2.3 mL/kg/min in pVO2 compared to metoprolol (p<0.0001) [4][6] - Aficamten also outperformed metoprolol in five of six secondary endpoints, including improvements in functional class and symptom burden [7][8] Safety Profile - The rate of adverse events was similar between aficamten and metoprolol, with aficamten showing a lower rate of treatment discontinuation due to adverse events [9] - Notably, hypertension was more common in the aficamten group, while dizziness was more prevalent in the metoprolol group [9] Regulatory Status - Aficamten is currently under review by the FDA with a target action date of December 26, 2025, and is also being evaluated by the European Medicines Agency [14][12]

Summary of Edgewise Therapeutics (EWTX) Conference Call Company Overview - **Company**: Edgewise Therapeutics (EWTX) - **Event**: 2025 Conference on May 20, 2025 Key Points on EDG-7500 in Hypertrophic Cardiomyopathy (HCM) 1. **Efficacy Profile**: EDG-7500 shows a unique efficacy profile with no changes in ejection fraction despite increased drug concentration, indicating a differentiated mechanism of action [3][6][10] 2. **Symptomatic Benefits**: 70% of patients became asymptomatic according to New York Heart Association (NYHA) classifications, with KCCQ scores improving by an average of over 20 points [6][9] 3. **Mechanism of Action**: The drug directly addresses hypertrophy without lowering ejection fraction, improving diastolic function and patient symptoms [5][6] 4. **Clinical Observations**: The absence of a placebo arm raised questions, but the deepening response at higher doses supports the drug's efficacy [7][8] 5. **Ejection Fraction Stability**: No relationship was found between drug concentration and changes in ejection fraction, reinforcing the drug's safety profile [10][12][15] 6. **Atrial Fibrillation Cases**: Four cases of atrial fibrillation were noted, but extensive preclinical studies showed no correlation with the drug's mechanism [16][19] 7. **Patient Enrollment Strategy**: Future trials will involve stricter patient selection criteria to minimize risks associated with atrial fibrillation [20][21][23] 8. **Titration Scheme**: The company is exploring a titration scheme that allows for individualized dosing based on patient response rather than relying solely on ejection fraction measurements [28][30][33] Upcoming Data Expectations 1. **Twelve-Week Data**: Anticipated trends in NT proBNP levels and potential deepening of efficacy in non-obstructive patients [25][27] 2. **Individualized Treatment Goals**: The aim is to achieve optimal dosing for each patient based on symptom relief and biomarker normalization [29][33] Sevasemten and DMD Data 1. **Patient Breakdown**: Upcoming data will include approximately 60-70 patients in the LINX group and 20-30 in the FOX group, focusing on biomarker and functional outcomes [38][39] 2. **Long-Term Efficacy**: Observations from previous studies indicate that benefits from gene therapy may diminish after two years, highlighting the need for ongoing assessment [40][41][42] 3. **FDA Discussions**: The company is on track for discussions regarding accelerated approval for Becker by the end of the quarter [44] Conclusion - Edgewise Therapeutics is advancing its clinical programs with a focus on individualized treatment strategies and robust data collection to support the efficacy and safety of its therapies in HCM and DMD. The upcoming data releases and regulatory discussions are critical for the company's future trajectory.